CGTX: Cognition Therapeutics Company Short-Term Debt

CGTX (Cognition Therapeutics) - company brandmark

Cognition Therapeutics (CGTX) is a pioneer in the therapy of neuronal degeneration, developing agents to block the impact of harmful proteins on synapses. The efficiency of clinical trials is ensured by outsourcing tasks to external laboratories and the proficient management of regulations. The current indicator is 0.00. This price chart illustrates the asset's market trend, reflecting the dynamics of the company's debt.

CGTX (Cognition Therapeutics) Company Current Liabilities history from 07/04/2022 to 10/31/2026

Analytical breakdowns for Cognition Therapeutics

- current quotes and average value forecast:
Price Chart Cognition Therapeutics, Inc.|CGTX - Fair Value Consensus
- market capitalization information:
Market Value Cognition Therapeutics, Inc.|CGTX - Total Enterprise Value
- shareholders' equity book value data:
Book Value per Share Cognition Therapeutics|CGTX - Company Net Assets|Market Value to Book Value Ratio cogrx.com|CGTX - Company Assets
- debt and liquidity details:
Total Debt to Capital Cognition Therapeutics|CGTX - Long-Term Indebtedness to Equity|Short-Term Debt to Equity Cognition Therapeutics|CGTX - Company Aggregate Debt|Debts to Book Capitalization Cognition Therapeutics, Inc.|CGTX - Long-Term Debt Volume|Company Current Liabilities Cognition Therapeutics|Quick Ratio cogrx.com
- net income and valuation multiples indicators:
CGTX - Net Financial Result
Fundamental valuation:Cognition Therapeutics, Inc. (CGTX)
Manufactured products of Cognition Therapeutics

The specific nature of the biotechnology sector for Cognition Therapeutics (CGTX) requires high liquidity to protect patent rights and conduct global trials amidst geopolitical risks. This metric captures obligations maturing within one year, reflecting the issuer's ability to service debt during supply volatility. Analyzing the current volume of short-term loans allows for an assessment of capital resilience against inflationary shocks. A decline in this curve confirms deleveraging, although it necessitates a review for potential revenue drops. It is critical for investors to correlate this indicator with the company's operational autonomy.

Competitors of Cognition Therapeutics

BIIB - Company Short-Term Debt|Company Short-Term Loans and Borrowings NBIX (Neurocrine)|Regencell (RGC) - Company Short-Term Debt|Short-Term Debt Axsome Corp (AXSM)|ACAD (ACADIA Pharmaceuticals) - Company Short-Term Debts|Company Current Liabilities xenon-pharma.com (XENE)|Company Short-Term Debt Viking Therapeutics, Inc. (VKTX)|SUPN - Short-Term Debt|Company Short-Term Debts CPRX (Catalyst Pharmaceuticals Inc)|Short-Term Indebtedness Denali Corp|HRMY - Company Short-Term Debt|BHVN (biohavenpharma.com) - Company Short-Term Indebtedness|AMLX: Company Short-Term Debts|TRVI - Short-Term Debt Volume|Company Current Liabilities PRAX|AVXL (Anavex Life Sciences Corp) - Amount of Current Liabilities|Company Short-Term Debts CBLL|Short-Term Debt Volume Prothena Corporation plc|Company Short-Term Debt Alector ALEC|Annexon Biosciences (ANNX) - Short-Term Debt|OMER - Company Short-Term Debt|NGNE (Neurogene Therapeutics) - Company Short-Term Indebtedness|ACIU (AC Immune) - Company Current Liabilities|voyagertherapeutics.com - Company Short-Term Loans and Borrowings|Company Current Liabilities NMRA|SCLX (Scilex Holding) - Amount of Current Liabilities|Company Short-Term Debts TVGN|ACOG (alphacognition.com) - Company Short-Term Loans and Borrowings|Company Short-Term Debts IKT (Inhibikase Therapeutics)|cassavasciences.com (SAVA) - Short-Term Debt|ASRT - Company Short-Term Debt|Company Short-Term Loans and Borrowings COYA (Coya Therapeutics, Inc.)|VTGN: Company Short-Term Debts|Ovid Therapeutics (OVID) - Company Short-Term Debts|Company Short-Term Debt Acumen Pharmaceuticals|cervomed.com - Current Liabilities|Company Short-Term Debts ATHE|CLNN - Short-Term Debt|PepGen - Company Current Liabilities|Company Short-Term Debts jupiterneurosciences.com JUNS|RLMD: Company Current Liabilities|annovisbio.com - Amount of Current Liabilities|GRCE: Company Short-Term Debts|AIFF - Short-Term Debt Volume|KLTO (ANEW Medical) - Company Short-Term Debts|Company Current Liabilities NeuroSense Therapeutics, Ltd. (NRSN)|Company Short-Term Debt Reviva Pharmaceuticals (RVPH)|Short-Term Debt Volume metaviatx.com|Company Short-Term Debts NRXS (NeurAxis)|HSDT - Company Current Liabilities|Passage Bio Corp - Company Short-Term Debts|Short-Term Indebtedness Neuphoria Therapeutics Inc. (NEUP)|NERV (Minerva Neurosciences) - Company Current Liabilities|ATHA: Amount of Current Liabilities|Company Current Liabilities ADXN|Company Short-Term Indebtedness ALZN (Alzamend)|Company Short-Term Debt Cyclerion Therapeutics (CYCN)|protagenic.com - Company Short-Term Indebtedness|Company Short-Term Debts KTTA (Pasithea Therapeutics Corp.)|Cortigent Inc (CRGT) - Short-Term Debt|ATXI: Company Current Liabilities|BCLI - Company Short-Term Debts|Cara Therapeutics, Inc (CARA) - Company Short-Term Debt|Chromocell - Company Short-Term Loans and Borrowings|Company Short-Term Debt Eliem Therapeutics, Inc.|Short-Term Debt Intra-Cellular ITCI|Company Short-Term Debts LBPH|Company Current Liabilities Marinus Pharmaceuticals Inc MRNS|Company Short-Term Debt NKGen NKGN|NeuroBo Pharma (NRBO) - Short-Term Debt|Sage Therapeutics, Inc. - Company Short-Term Debts|Short-Term Indebtedness synaptogen.com (SNPX)|Trevena (TRVN) - Company Short-Term Debt|Company Short-Term Indebtedness VIGL|WENA (Anew Medical, Inc.) - Company Short-Term Debts|Cerevel Corp (CERE) - Short-Term Debt Volume